Jefferies keeps GBp 17,500 target for AstraZeneca stock

Published on 10/13/2026 at 13:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca's third-quarter results are scheduled for October 30, 2026. AstraZeneca stock costs EUR 144.88 on October 13, 2026 during German trading.

Key points in brief

On October 7, 2026, Jefferies kept its Buy rating and GBp 17,500 target for AstraZeneca.
AstraZeneca's next scheduled earnings date is October 30, 2026.
AstraZeneca stock was EUR 144.88 at Lang & Schwarz on October 13, 2026 at 1:01 p.m. CEST.
The price to earnings ratio was 23.67 and the dividend yield was 2.01 percent as of October 12, 2026.

Isometrische 3D-Grafik zeigt Labor, Produktion und Pharma-Logistikkette — AstraZeneca plc (ISIN GB0009895292) steuert eine komplexe Wertschöpfungskette von Forschung bis zur globalen Arzneimittel-Distribution, Illustration mit AI erstellt.

Jefferies kept its Buy rating and GBp 17,500 price target for AstraZeneca on October 7, 2026, compared with the broker's cited GBp 11,958 share price. The target represented 46.00 percent potential upside, according to Proactive. AstraZeneca was EUR 144.88 at Lang & Schwarz on October 13, 2026 at 1:01 p.m. CEST.

Results arrive on October 30

AstraZeneca's next earnings date is October 30, 2026, according to the earnings calendar displayed by Yahoo Finance. The date gives the market a defined checkpoint for the company's third-quarter performance and the outlook for the rest of fiscal 2026.

London listing stays the key reference

AstraZeneca's primary listing is on the London Stock Exchange under ticker AZN.L, with the shares quoted in GBp. The London close was GBp 11,998.00 on October 9, 2026, as reported by Global Banking and Finance. The Lang & Schwarz euro quote is a separate German-market indication and should not be combined with the London price in a single return calculation.

Valuation and income profile

On October 12, 2026, AstraZeneca's US-listed quote was USD 158.33, while its 52-week range was USD 153.41 to USD 212.71. The same quote page showed a market capitalization of USD 245.6 billion, a price to earnings ratio of 23.67 and a dividend yield of 2.01 percent. Those figures provide the valuation frame alongside Jefferies' GBp target, but the currencies are different and are not netted against the euro quote.

Comparison with peers

AstraZeneca: price to earnings ratio 23.67, market capitalization USD 245.6 billion
GSK (NYSE, USD): price to earnings ratio 14.99, market capitalization USD 94.0 billion
Novartis (NYSE, USD): price to earnings ratio 22.29, market capitalization USD 273.4 billion

Trading reference in Germany

The Lang & Schwarz quote stood at EUR 144.88 on October 13, 2026 at 1:01 p.m. CEST, with a bid of EUR 144.75 and an ask of EUR 145.00. No cross-currency comparison is made between this euro quote and AstraZeneca's London or US-listed values. The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.